UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue

British journal of haematology, 2000-08, Vol.110 (2), p.292-299

2000

Link zum Volltext

Verfügbarkeit prüfen

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

European journal of cancer (1990), 2018-11, Vol.104, p.160-168

2018

Link zum Volltext

Verfügbarkeit prüfen

LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

Annals of oncology, 2021-09, Vol.32, p.S1283-S1283

2021

Link zum Volltext

Verfügbarkeit prüfen

The incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer

Annals of oncology, 2019-05, Vol.30, p.iii35-iii36

2019

Link zum Volltext

Verfügbarkeit prüfen

275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)

Annals of oncology, 2020-09, Vol.31, p.S349-S350

2020

Link zum Volltext

Verfügbarkeit prüfen

334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection

Annals of oncology, 2020-09, Vol.31, p.S380-S380

2020

Link zum Volltext

Verfügbarkeit prüfen

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

Annals of oncology, 2020-09, Vol.31, p.S1147-S1148

2020

Link zum Volltext

Verfügbarkeit prüfen

288P Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

Annals of oncology, 2020-09, Vol.31, p.S356-S357

2020

Link zum Volltext

Verfügbarkeit prüfen

278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients

Annals of oncology, 2020-09, Vol.31, p.S351-S352

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)

Annals of oncology, 2019-05, Vol.30, p.iii63-iii64

2019

Link zum Volltext

Verfügbarkeit prüfen

LBA23 - MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

Annals of oncology, 2019-10, Vol.30, p.v861-v862

2019

Link zum Volltext

Verfügbarkeit prüfen

MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

Annals of oncology, 2019-10, Vol.30, p.v861-v862

2019

Link zum Volltext

Verfügbarkeit prüfen

Primary tumour Ki67 predicts endocrine sensitivity in ER positive metastatic breast cancer (MBC)

European journal of cancer supplements, 2008, Vol.6 (7), p.190-190

2008

Link zum Volltext

Verfügbarkeit prüfen

Increasing Her2/Centromere17(CEP17) ratio predicts for greater sensitivity to trastuzumab based therapy in metastatic breast cancer (MBC)

European journal of cancer supplements, 2008, Vol.6 (7), p.192-192

2008

Link zum Volltext

Verfügbarkeit prüfen

A quantitative histometric murine in vivo model of radiation-induced oral mucositis

Archives of oral biology, 1998-07, Vol.43 (7), p.567-577

1998

Link zum Volltext

Verfügbarkeit prüfen

Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis

The Journal of infection, 1996-07, Vol.33 (1), p.43-45

1996

Link zum Volltext

Verfügbarkeit prüfen

Changes in Ejection Fraction (EF) Following Sequential Anthracycline and Trastuzumab in Patients with HER2+ Early Breast Cancer (EBC) – Is There a Need for Two Echocardiograms Pre-trastuzumab?

Clinical oncology (Royal College of Radiologists (Great Britain)), 2017-06, Vol.29 (6), p.e99-e99

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Annals Of Oncology
(13)
European Journal Of Cancer Supplements
(2)
Archives Of Oral Biology
(1)
British Journal Of Haematology
(1)
Clinical Oncology
(1)
European Journal Of Cancer
(1)
The Journal Of Infection
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

The incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer

275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)

334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

288P Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients

A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)

LBA23 - MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

314P - Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

Primary tumour Ki67 predicts endocrine sensitivity in ER positive metastatic breast cancer (MBC)

Increasing Her2/Centromere17(CEP17) ratio predicts for greater sensitivity to trastuzumab based therapy in metastatic breast cancer (MBC)

A quantitative histometric murine in vivo model of radiation-induced oral mucositis

Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis

Changes in Ejection Fraction (EF) Following Sequential Anthracycline and Trastuzumab in Patients with HER2+ Early Breast Cancer (EBC) – Is There a Need for Two Echocardiograms Pre-trastuzumab?

Suchergebnisse filtern